Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02204904 · ClinicalTrials.gov registry record
Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)
A clinical trial, sponsored by Genetix Biotherapeutics.
- Terminated
- Registry status
- 59
- Enrollment target
NCT02204904 is a clinical trial that was terminated before completion, run by Genetix Biotherapeutics. The registered enrollment target is 59 participants.
The verdict
NCT02204904 was terminated before completion, sponsored by Genetix Biotherapeutics.
- TERMINATED
- Registry status
- 59 participants
- Enrollment target
Study Summary
Study ALD-103 will be a multi-site, global, prospective and retrospective data collection study that is designed to evaluate outcomes of allo-HSCT in male subjects with CALD ≤17 years of age.
Interventions
- GENETIC Allo-HSCT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2015-04 |
| Est. Completion | 2019-12-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02204904
The ClinicalTrials.gov registry entry for NCT02204904 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genetix Biotherapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Allo-HSCT is the first listed.
NCT02204904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02204904 about?
NCT02204904 is a clinical study titled "Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)". Study ALD-103 will be a multi-site, global, prospective and retrospective data collection study that is designed to evaluate outcomes of allo-HSCT in male subjects with CALD ≤17 years of age.
What is the current status of trial NCT02204904?
This trial is currently terminated. The enrollment target is 59 participants. The study started on 2015-04. Estimated completion is 2019-12-06.
What interventions are being tested in trial NCT02204904?
The interventions under investigation include: Allo-HSCT (GENETIC).
Who is sponsoring clinical trial NCT02204904?
This trial is sponsored by Genetix Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.